Coffin Carla S, Fung Scott K, Ma Mang M
Department of Medicine, University of Calgary, Alberta.
Can J Gastroenterol. 2012 Dec;26(12):917-38. doi: 10.1155/2012/506819.
Chronic hepatitis B (CHB) is a dynamic disease that is influenced by host and virological factors. The management of CHB has become more complex with the increasing use of long-term oral nucleos⁄tide analogue antiviral therapies and the availability of novel diagnostic assays. Furthermore, there is often a lack of robust data to guide optimal management such as the selection of therapy, duration of treatment, potential antiviral side effects and the treatment of special populations. In November 2011, the Canadian Liver Foundation and the Canadian Association for the Study of the Liver convened a consensus conference to review the literature and analyze published data, including other international expert guidelines on CHB management. The proceedings of the consensus conference are summarized and provide updated clinical practice guidelines to assist Canadian health care providers in the prevention, diagnosis, assessment and treatment of CHB.
慢性乙型肝炎（CHB）是一种受宿主和病毒学因素影响的动态疾病。随着长期口服核苷/核苷酸类似物抗病毒疗法的使用增加以及新型诊断检测方法的出现，CHB的管理变得更加复杂。此外，通常缺乏有力的数据来指导最佳管理，例如治疗选择、治疗持续时间、潜在的抗病毒副作用以及特殊人群的治疗。2011年11月，加拿大肝脏基金会和加拿大肝脏研究协会召开了一次共识会议，以回顾文献并分析已发表的数据，包括其他关于CHB管理的国际专家指南。本次共识会议的议程进行了总结，并提供了最新的临床实践指南，以协助加拿大医疗保健提供者对CHB进行预防、诊断、评估和治疗。
